28 series
Export
<<< of 2>>>
Accession Title Series type(s) Organism(s) Samples GDS Supplementary Contact Release date
Remove filtersFilter Remove filterRhodotorula
GSE99872
Therapeutic antibodies to ganglioside GD2 evolved from highly selective germline antibodies I
6 Jeff Gildersleeve Aug 25, 2017
GSE99873
Therapeutic antibodies to ganglioside GD2 evolved from highly selective germline antibodies II
14 Jeff Gildersleeve Aug 25, 2017
GSE99874
Therapeutic antibodies to ganglioside GD2 evolved from highly selective germline antibodies III
7 Jeff Gildersleeve Aug 25, 2017
GSE100307
Therapeutic antibodies to ganglioside GD2 evolved from highly selective germline antibodies IV
7 Jeff Gildersleeve Aug 25, 2017
GSE100308
Therapeutic antibodies to ganglioside GD2 evolved from highly selective germline antibodies V
7 Jeff Gildersleeve Aug 25, 2017
GSE100309
Therapeutic antibodies to ganglioside GD2 evolved from highly selective germline antibodies VI
7 Jeff Gildersleeve Aug 25, 2017
GSE100310
Therapeutic antibodies to ganglioside GD2 evolved from highly selective germline antibodies VII
7 Jeff Gildersleeve Aug 25, 2017
GSE100438
Therapeutic antibodies to ganglioside GD2 evolved from highly selective germline antibodies
55 Jeff Gildersleeve Aug 25, 2017
GSE68403
Development of a glycan microarray based method for ABO blood typing
220 Jeff Gildersleeve Apr 28, 2016
GSE68405
A Simple, Inexpensive Strategy for Predicting Potential Beneficial Clinical Responses on Prostate Cancer Vaccine Therapy
331 Jeff Gildersleeve Apr 28, 2016
GSE50230
Post-vaccination serum anti-glycan IgG antibodies of 28 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine. (Dilution = 1:50)
28 Christopher Campbell Aug 26, 2015
GSE50231
Post-vaccination serum anti-glycan IgM antibodies of 28 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine. (Dilution = 1:50)
28 Christopher Campbell Aug 26, 2015
GSE50232
Post-vaccination serum anti-glycan total Ig antibodies of 28 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine. (Dilution = 1:50)
28 Christopher Campbell Aug 26, 2015
GSE50233
Post-vaccination serum anti-glycan total Ig antibodies of 28 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine. (Dilution = 1:200)
28 Christopher Campbell Aug 26, 2015
GSE50235
Post-vaccination serum anti-glycan IgG antibodies of 113 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine. (Dilution = 1:50)
113 Christopher Campbell Aug 26, 2015
GSE50236
Baseline serum anti-glycan total Ig antibodies of 113 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine. (Dilution = 1:50)
113 Christopher Campbell Aug 26, 2015
GSE50237
Baseline serum anti-glycan IgM antibodies of 113 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine. (Dilution = 1:50)
113 Christopher Campbell Aug 26, 2015
GSE50239
Post-vaccination serum anti-glycan total Ig antibodies of 113 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine. (Dilution = 1:200)
113 Christopher Campbell Aug 26, 2015
GSE50410
Anti-glycan humoral responses after vaccination with PROSTVAC-VF
564 Christopher Campbell Aug 26, 2015
GSE42019
Baseline serum anti-glycan antibodies of 28 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine [Training IgG 1:50]
28 Christopher Campbell Apr 01, 2013